Who Is at Risk of Penile Cancer?

Understanding Penile Cancer: Rare But Real

Penile cancer — malignancy arising from the skin and tissues of the penis — is one of the rarest urological cancers in the developed world, yet its rarity is precisely what makes it dangerous. Men dismiss unusual symptoms for months or years, assuming that something so uncommon could never affect them. When diagnosis finally arrives, the disease is often at an advanced stage.

The majority of penile cancers — roughly 95% — are squamous cell carcinomas, originating in the flat, scale-like cells of the penile skin. A smaller proportion are basal cell carcinomas, melanomas, or, rarely, sarcomas. The glans and the foreskin are the most common sites of origin, accounting for more than 80% of cases.

What makes penile cancer clinically significant despite its rarity is the devastating impact of late-stage treatment. Partial or total penectomy may be required in advanced cases, profoundly affecting quality of life, urinary function, sexual health, and psychological wellbeing. Most men diagnosed with penile cancer waited an average of more than six months after first noticing symptoms before seeking medical attention. That delay — driven by embarrassment, fear, or false reassurance — is the single most modifiable factor in outcomes.

Who Is Most at Risk?

Penile cancer does not arise randomly. It clusters around a set of well-characterised biological, behavioural, and environmental risk factors. Some of these cannot be changed, such as age and anatomy; others absolutely can be. No single factor alone typically drives penile cancer — it is most often a convergence. An uncircumcised man who smokes, has phimosis, and carries a high-risk HPV strain faces a substantially higher cumulative risk than any individual factor would suggest. Risk is multiplicative, not merely additive.

The HPV Connection: The Virus at the Core

Human Papillomavirus is the most important modifiable risk factor for penile cancer. Studies using modern DNA detection techniques find high-risk HPV strains — predominantly HPV-16 and HPV-18 — in between 40% and 60% of all penile squamous cell carcinomas. In some subtypes, particularly basaloid and warty variants, HPV prevalence approaches 80–90%.

How HPV Drives Malignancy

HPV is a double-stranded DNA virus with more than 200 recognised strains. Once high-risk HPV infects the squamous epithelium of the penis, two viral proteins — E6 and E7 — interfere with the cell's own tumour-suppressor machinery. E6 degrades p53, the so-called guardian of the genome that triggers programmed cell death in damaged cells. E7 inactivates retinoblastoma protein, which normally blocks uncontrolled cell division. Together, these mechanisms remove the cell's built-in brakes on proliferation.

This doesn't happen overnight. The journey from initial HPV infection to invasive carcinoma typically takes 10 to 30 years, passing through progressively abnormal precancerous states called penile intraepithelial neoplasia. This long latency window is an enormous opportunity for intervention.

HPV-16 is responsible for the majority of HPV-positive penile cancers and is the same strain responsible for most cervical cancers. HPV-18 is the second most common high-risk strain. HPV-6 and HPV-11 are low-risk strains that cause genital warts but are not directly oncogenic.

Sexual Behaviour and HPV Exposure

Because HPV spreads through skin-to-skin genital contact rather than bodily fluids alone, transmission occurs even with condom use — condoms reduce risk by an estimated 60–70% but do not eliminate it. Key behavioural risk factors include a high lifetime number of sexual partners, early age of first sexual intercourse, and sexual activity with partners who have themselves had multiple partners.

The HPV vaccine (Gardasil 9) protects against HPV-16, 18, and five other high-risk strains. It is most effective when administered before first sexual exposure — ideally at age 11–12 — but guidelines in many countries now recommend vaccination up to age 26 routinely, and up to age 45 with individual clinical assessment. Men and boys are eligible and strongly encouraged to vaccinate.

Phimosis and Chronic Inflammation: A Hidden Structural Risk

Phimosis — a condition in which the foreskin cannot be fully retracted over the glans — is one of the most consistently identified risk factors for penile cancer. Men with phimosis have been found to have a relative risk of penile cancer approximately 3 to 6 times higher than men without the condition.

Smegma accumulates under the foreskin in men who cannot retract it, creating a persistent irritant environment that promotes ongoing inflammation and may amplify the effects of other carcinogens, including those from tobacco. The moist, warm preputial space also becomes an ideal reservoir for HPV persistence — if the foreskin cannot be fully retracted, the immune system has less opportunity to mount an effective response against viral infection. Additionally, chronic inflammation generates reactive oxygen and nitrogen species that damage DNA, creating a microenvironment rich in growth factors that can promote abnormal cell proliferation.

Among men diagnosed with penile cancer, studies have found that between 25% and 75% had a history of phimosis — a striking over-representation given phimosis affects roughly 1–3% of adult men globally.

Lichen Sclerosus: A Related Risk

Balanitis xerotica obliterans — the genital manifestation of lichen sclerosus — is a chronic inflammatory skin disease that often causes or exacerbates phimosis. Studies suggest between 2% and 9% of men with lichen sclerosus may eventually develop penile cancer if the condition is untreated. It is considered a precancerous condition requiring ongoing surveillance.

Smoking and Chemical Carcinogens

Tobacco smoking is an independent, dose-dependent risk factor for penile cancer. Men who smoke carry an estimated 3 to 4.5 times higher risk compared to non-smokers, with risk increasing with the number of pack-years of smoking history.

The mechanism operates through two main pathways. First, tobacco carcinogens — including polycyclic aromatic hydrocarbons, nitrosamines, and aromatic amines — are excreted in genital secretions, directly bathing the epithelium of the penis in mutagenic compounds. Second, smoking impairs local and systemic immune function, reducing the body's capacity to clear HPV infections before they establish persistence.

A man who smokes and has phimosis and an untreated HPV infection is not facing three separate, additive risks — these factors interact synergistically, and his actual cancer risk is multiplicatively elevated. Quitting smoking at any point reduces this elevated risk.

PUVA phototherapy — used to treat psoriasis — involves exposure to psoralen compounds and ultraviolet-A light. Studies have found that men who received more than 250 PUVA treatments had significantly elevated rates of penile and scrotal cancers. Modern PUVA protocols use genital shielding specifically because of this risk.

Age, Geography, and Socioeconomic Factors

Penile cancer is overwhelmingly a disease of older men. The median age at diagnosis is approximately 68 years in the United States, and more than 75% of cases occur in men over 55. Age accumulates the consequences of prior risk factor exposures — years of chronic HPV carriage, decades of inflammatory changes from phimosis, the compounding effects of tobacco — and simultaneously reduces immune surveillance capacity.

Global Geographic Disparity

In North America, Australia, and Northern Europe, incidence rates hover between 0.5 and 1 case per 100,000 men annually. In parts of sub-Saharan Africa, South America, and South and Southeast Asia, rates can be 5 to 10 times higher. This disparity reflects converging risk factors: lower circumcision rates, limited HPV vaccination access, higher HPV infection rates, constrained healthcare access, and higher smoking rates.

Within the United States, Black and Hispanic men have modestly higher rates of penile cancer compared to non-Hispanic White men. These differences likely reflect disparities in HPV vaccination uptake, circumcision rates, access to primary care, and socioeconomic factors — not genetic differences in susceptibility, but reflections of structural health inequity.

Hygiene, Smegma, and Chronic Irritation

Chronic irritation and inflammation of penile tissue, from any cause, creates conditions that favour malignant transformation over time. In uncircumcised men who can retract the foreskin, regular cleaning of the preputial space with warm water daily is straightforward and highly protective. The situation is genuinely different in men with phimosis, where effective cleaning is anatomically impossible without medical intervention — which is one reason why treating phimosis is medically important, not merely a cosmetic or comfort issue.

The protective effect of neonatal circumcision on penile cancer risk is one of the most consistently replicated findings in urological oncology. Multiple large studies have found that circumcision, particularly when performed in infancy, reduces penile cancer risk by approximately 3-fold, operating through clear mechanisms: eliminating the preputial space that facilitates smegma retention, HPV trapping, and chronic inflammation.

Immune Suppression: When the Body Cannot Defend Itself

The immune system plays a central role in containing HPV infections and eliminating cells that have undergone early pre-malignant transformation. When immune function is compromised — by HIV infection, organ transplant immunosuppression, or autoimmune conditions — the risk of HPV-related cancers rises substantially.

HIV-positive men carry a significantly elevated risk of penile cancer — estimated at approximately 3 to 8 times higher than HIV-negative men. This reflects the direct immune compromise caused by HIV, which impairs CD4+ T-cell mediated clearance of HPV-infected cells. In the era of antiretroviral therapy, this risk persists even in men with well-controlled viral loads.

Solid organ transplant recipients require chronic, high-dose immunosuppressive therapy to prevent rejection, dramatically elevating rates of all HPV-associated cancers including penile cancer. The risk increases with time since transplantation and intensity of immunosuppression. HPV vaccination before transplantation is strongly recommended where possible.

Warning Signs Every Man Should Know

Penile cancer almost always announces itself with visible or palpable changes — it is not a hidden internal cancer. Early detection is theoretically achievable in most cases. The tragedy is that men fail to act on symptoms they notice, often for six months to several years.

Any persistent change on the penis that does not resolve within four weeks should be evaluated by a doctor. These are not symptoms to monitor at home.

Symptoms Requiring Prompt Medical Evaluation

A persistent sore, ulcer, or lesion — a wound or sore on the glans, shaft, or foreskin that does not heal within four weeks — may or may not be painful and is sometimes mistaken for a healing injury or STI. Any new thickened area, flat growth, wart-like mass, or raised lesion anywhere on the penis also requires evaluation, as does any change in colour or texture such as patches that have become white, red, or very dark.

Bleeding or unusual discharge from the penis not related to obvious injury, a persistent rash under the foreskin that does not respond to basic hygiene or antifungal treatment, swollen lymph nodes in the groin, and any change in urinary stream may all be indicators of penile cancer and require prompt medical attention.

Common Myths vs. Facts

Myth: Penile cancer only affects men with poor hygiene.

HPV — not hygiene — is the primary driver in most cases. Well-hygienised HPV-positive men with phimosis remain at elevated risk. Hygiene matters, but it is one factor among many.

Myth: If you're circumcised, you can't get penile cancer.

Circumcision substantially reduces risk but does not eliminate it. Approximately 30–50% of penile cancer cases in developed countries occur in circumcised men. HPV vaccination and monitoring remain important regardless.

Myth: HPV vaccines are for women and girls only.

HPV vaccines are approved, recommended, and effective for males. They protect against the HPV strains responsible for penile cancer, anal cancer, oropharyngeal cancer, and genital warts in men.

Myth: A sore on the penis is definitely an STI, not cancer.

Many penile cancers are initially misdiagnosed as STIs, fungal infections, or dermatological conditions — by the patient and sometimes by clinicians. Any lesion that fails to resolve within four weeks requires biopsy consideration, not just empirical treatment.

Myth: Penile cancer is always caused by sexual promiscuity.

HPV transmission requires only sexual contact — including with a single partner over a lifetime. Non-HPV-associated penile cancers arise from phimosis, smoking, and other factors entirely unrelated to sexual behaviour. Stigma around this diagnosis actively delays men seeking care.

Prevention: A Practical Roadmap

The majority of penile cancer cases are, in principle, preventable. The risk factors are well understood, and effective interventions exist for most of them.

Getting the HPV vaccine is the single most powerful preventive step available. Gardasil 9 covers the most oncogenic strains and is beneficial at any age before 45, though most effective before first sexual exposure.

Addressing phimosis is medically important. If you cannot retract your foreskin fully, see a urologist. Treatment options range from topical steroid creams, which are effective in 60–80% of mild cases, to surgical intervention. Quitting smoking reduces penile cancer risk alongside overall cancer risk — every year of cessation matters.

Practising consistent genital hygiene through daily gentle cleaning of the glans and preputial space with warm water, using condoms during sexual activity to reduce HPV transmission risk, and managing lichen sclerosus with regular follow-up and topical corticosteroids all contribute meaningfully to risk reduction.

For HIV-positive men, maintaining viral suppression with antiretroviral therapy preserves immune function. Monthly self-examination of the penis takes 60 seconds and creates familiarity with what is normal — any new lesion or change that persists beyond four weeks warrants medical evaluation.

When to See a Doctor

There is no formal population-level screening programme for penile cancer. The burden of early detection falls squarely on individual men who must self-examine and seek care when they notice changes, and on clinicians who must consider penile cancer when men present with persistent genital symptoms.

For men in higher-risk categories — those with phimosis, lichen sclerosus, long-standing HIV, or a history of high-risk HPV infection — more active surveillance by a urologist or dermatologist is appropriate. Annual genital examination as part of a routine health check is reasonable for men over 55 in any risk category.

What Happens at Evaluation

A clinician evaluating a penile lesion will take a full history, perform a thorough visual and tactile examination, and may use peniscopy to delineate lesion extent. Any suspicious lesion will be biopsied — a small, local procedure that provides definitive histological diagnosis. Imaging is used if cancer is confirmed and staging is required.

Penile cancer caught at Stage I — confined to the skin and superficial tissue — has an 85% five-year survival rate and is often treatable with penis-conserving surgery. Caught at Stage IV, five-year survival drops below 10%. The difference between these two outcomes is, very often, a matter of months of delay or action — and that is entirely within individual control.

---

Medical Disclaimer: This document is intended for general health education and informational purposes only. It does not constitute medical advice, diagnosis, or a treatment plan. If you have symptoms or concerns discussed in this document, please consult a physician without delay.